Transform Your Pharmacy’s Growth Potential with ACHC and Monarch Specialty Group. Click Here to learn more

October 2013



We support a broad collection of relevant news information for clients, as well as organizations evaluating our services.
Get market insights and strategies on orphan drugs and specialty drug pipeline, drug pricing, mergers and acquisitions, and up-to-date payor strategies relating to oncology, infectious disease (Hepatitis-C and HIV), multiple sclerosis, IVIG, and biosimilars, among others:

MS Space Experienced Massive Price Inflation

… in which this trend has been evident, according to Stephen Cichy, founder and managing director for Monarch Specialty Group, LLC during a … was nothing particularly alarming,” said Cichy. During that time period, when there were “no other changes and no … was approved in August 2010, were shared. According to Cichy, “the average cost per claim for Copaxone for March 2012 was $4,088.07, …